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CLINICAL/SCIENTIFIC NOTES OPEN ACCESS
Expanding the ADCY5 phenotype toward
spastic paraparesis
Amutation in theM2 domain
Anne J.E. Waalkens, MD, Fleur Vansenne, MD, PhD, Annemarie H. van der Hout, MD, PhD, Rodi Zutt, MD,
JeroenMourmans,MD, Eduardo Tolosa,MD, PhD, Tom J. de Koning,MD, PhD, andMarinaA.J. Tijssen,MD, PhD




Patients with an ADCY5 gene mutation reveal a heterogenous clinical presentation including
axial hypotonia, motor milestone delay, ﬂuctuating dyskinesias, dystonia, and/or myoclonus
with episodic exacerbations during drowsiness and sleep.1,2 Phenotype-genotype correlations
and somatic mosaicism are suggested to explain the wide phenotypic spectrum.1
The ADCY5 gene encodes 1 of 9 membrane-bound adenyl cyclases converting adenosine
triphosphate to cyclic adenosine-39, 59-monophosphate, the second messenger in a range of
cellular activities.3 The ADCY5 protein contains 2 transmembrane domains, M1 and M2, and
2 bipartite cytoplasmic domains, C1 and C2. Pathogenic mutations have been described in
domains C1 and C2.1,2 Mutations are likely to have a gain-of-function eﬀect based on increased
cyclic adenosine-39, 59-monophosphate accumulation.4
The present report describes 3 cases of ADCY5 dyskinesia to further illustrate the clinical
spectrum: a new phenotype, i.e., spastic paraparesis due to a mutation located in the M2
domain; case 1, case 2, and case 3 show previously described mutations in the C1 domain of the
ADCY5 protein. Their phenotypes show important similarities to previous cases, with the
addition of the psychiatric symptoms of the patient in case 3.
Case 1
A 40-year-old woman was referred to our clinic with a 6-year history of progressive fatigue,
painful movements, and muscle weakness of the lower limbs. History revealed delayed ability
to sit independently until the age of 2 years, most likely due to early axial hypotonia, with
subsequent catching up of motor development. Family history revealed no movement dis-
orders. Neurologic examination showed spastic paraparesis, with hyperreﬂexia, hypertonia in
the legs, and extensor plantar reﬂexes. There was mild dystonic posturing of the right foot while
walking and writer’s cramp of the right hand. As the dystonic features were not recognized as
such before, the age at onset is not clear. MRI of the brain and spine and metabolic blood
examination were unremarkable.
Whole-exome sequencing revealed a c.2722G>A, p.(Glu908Lys) mutation in the ADCY5 gene.
Her mother is mosaic for the mutation in peripheral blood (proportion mutation: wild type
about 1:3) without a relevant medical history or current complaints.
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Case 2
A 1.5-year-old girl was presented to our clinic with motor
milestone delay and dyskinesias. Pregnancy and delivery
were unremarkable. Hypotonia and involuntary move-
ments were ﬁrst noticed at the age of 9 months. Family
history was negative. Neurologic examination showed axial
hypotonia and generalized chorea, more pronounced by
action, with facial involvement. There was hyperreﬂexia
without spasticity. Mother described exacerbations of dys-
kinesia during sleep. Genetic testing revealed a “de novo”
previously reported c.1252C>T p.(Arg418Trp) mutation
in the ADCY5 gene.1,2
Case 3
A 16-year-old young woman was presented to the outpatient’s
clinic in Barcelona with episodic dyskinesias with oral in-
volvement since the age of 18 months. At this age, she started
walking independently with frequent falls. From 12 years of age,
she developed tics, coprolalia, and prominent obsessive com-
pulsive and anxiety disorder with phobias. At the age of 16 years,
she presented with nonﬂuent speech, myoclonus, and chorea of
the face and upper limbs and mild dystonic posturing of the
limbs with episodic exacerbations. Family history revealed no
movement, behavioral of psychiatric disorders. Genetic testing,
using a dystonia panel, i.e., combined “next-generation” and
Sanger sequencing method, showed a previously described
c.1253G>A p.(Arg418Gln) mutation in the ADCY5 gene.1,2
The 3 new ADCY5 cases support the wide phenotypic pre-
sentation of ADCY5 gene mutations in the literature. We add
another phenotype, i.e., spastic paraparesis due to a mutation
in the M2 domain of the ADCY5 protein (case 1). This mu-
tation is predicted pathogenic by in silico prediction tools and
is absent in available data sets of population controls.
Spasticity, hyperreﬂexia, and bilateral extensor plantar reﬂexes
were mentioned as additional features in several cases with
mutation(s) in a cytoplasmic (C) domain.2,5,6 The somatic
mosaicism present in the index’s mother demonstrates that
mosaicism can lead to a (much) milder to no phenotype at
all.1 Future studies are of interest to detect the relevance of
ADCY5 mutations in patients with paraparesis.
Cases 2 and 3 showmutations in the C1 domain of the ADCY5
gene. These 2 mutations have been previously described with
comparable dyskinetic phenotypes1,2; however, case 3 patient’s
(prominent) psychiatric symptoms are distinctive. If the psy-
chiatric manifestations can be ascribed to the ADCY5 pheno-
type remains unclear, given these prevalence of psychiatric
disorders in the general population. An association between
ADCY5 mutations and psychiatric symptoms is conceivable.
Our 3 cases further support the conclusion of a heterogenous
phenotype and a possible phenotype-genotype correlation as
suggested in ADCY5-mutation–associated disease.
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